Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
AIM:To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD). METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2013-04-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633755/ |
| _version_ | 1811326859217993728 |
|---|---|
| author | Zhe-Li Liu Feng Gu Peng Sun Han Zhang Jun Li |
| author_facet | Zhe-Li Liu Feng Gu Peng Sun Han Zhang Jun Li |
| author_sort | Zhe-Li Liu |
| collection | DOAJ |
| description | AIM:To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD). METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events. RESULTS:At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72±0.23 and 0.73±0.22 to 0.47±0.14 and 0.45±0.20, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71±34.72μm and 352±36.9μm at baseline to 250.86±41.51μm and 243.22±41.38μm in the bevacizumab and ranibizumab groups, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events. CONCLUSION:Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term. |
| first_indexed | 2024-04-13T14:56:46Z |
| format | Article |
| id | doaj.art-13f5cb67a9544e45a980524a858f3b9b |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-04-13T14:56:46Z |
| publishDate | 2013-04-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-13f5cb67a9544e45a980524a858f3b9b2022-12-22T02:42:25ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982013-04-016216917310.3980/j.issn.2222-3959.2013.02.12Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patientsZhe-Li LiuFeng GuPeng SunHan ZhangJun LiAIM:To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD). METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events. RESULTS:At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72±0.23 and 0.73±0.22 to 0.47±0.14 and 0.45±0.20, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71±34.72μm and 352±36.9μm at baseline to 250.86±41.51μm and 243.22±41.38μm in the bevacizumab and ranibizumab groups, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events. CONCLUSION:Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633755/age-related macular degenerationchoroidal neovascularizationbevacizumab (avastin)ranibizumab (lucentis) |
| spellingShingle | Zhe-Li Liu Feng Gu Peng Sun Han Zhang Jun Li Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients International Journal of Ophthalmology age-related macular degeneration choroidal neovascularization bevacizumab (avastin) ranibizumab (lucentis) |
| title | Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients |
| title_full | Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients |
| title_fullStr | Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients |
| title_full_unstemmed | Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients |
| title_short | Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients |
| title_sort | bevacizumab vs ranibizumab for neovascular age related macular degeneration in chinese patients |
| topic | age-related macular degeneration choroidal neovascularization bevacizumab (avastin) ranibizumab (lucentis) |
| url | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633755/ |
| work_keys_str_mv | AT zheliliu bevacizumabvsranibizumabforneovascularagerelatedmaculardegenerationinchinesepatients AT fenggu bevacizumabvsranibizumabforneovascularagerelatedmaculardegenerationinchinesepatients AT pengsun bevacizumabvsranibizumabforneovascularagerelatedmaculardegenerationinchinesepatients AT hanzhang bevacizumabvsranibizumabforneovascularagerelatedmaculardegenerationinchinesepatients AT junli bevacizumabvsranibizumabforneovascularagerelatedmaculardegenerationinchinesepatients |